Masimo, a leader in innovative non-invasive monitoring technologies, has released the MightySat Rx fingertip pulse oximeter for clinical use in CE countries.

It is offering the same Masimo SET Measure-Through Motion and Low Perfusion pulse oximetry technology used in the world’s leading hospitals, said a statement.

Bluetooth-enabled versions of MightySat Rx allow clinicians to track and trend up to 12 hours of patient measurements on smart mobile devices, and to share that data via standard CSV files as well as transfer to Apple’s Health app.

MightySat Rx will enable accurate non-invasive spot-checking of oxygen saturation (SpO2) and pulse rate (PR) for adult and paediatric patients even during motion and low perfusion.

It will measure and display Perfusion Index (PI), which reflects the strength of the pulsatile signal.

MightySat can also measure and display Pleth Variability Index (PVI), a measure of the dynamic changes in the perfusion index that occur during one or more complete respiratory cycle/s.

Joe Kiani, founder and chief executive officer, said: “Many clinicians around the world rely on pulse oximetry as the fifth vital sign. The MightySat Rx represents a significant milestone. To deliver Masimo SET performance in this low-power form factor took some engineering, given the precision of our technology and SET’s computationally intensive algorithm.

“We actually dropped the power consumption by nearly two orders of magnitude. But the development effort was worth it, as we expect this technology will empower clinicians and they will no longer have to compromise performance for mobility.” - TradeArabia News Service